Bausch's Lumify Eye Drops Sales Jump To Double Competitors' Market Share
Lumify redness relief eye drops nearly doubled in sales between Bausch's second and third quarters and drove 7% organic growth of its global consumer business compared to the year-ago period. The brand has double the market share of its two closest competitors, and the firm plans clinical studies for product extensions to the brand in 2020.
You may also be interested in...
Switch consultant Susan Levy suggests drug firms temper enthusiasm for Rx-to-OTC switches with considering the costs NDAs generate and the histories of switches that haven’t been successes.
Bausch says it expects US FDA to approve its ANDA for the first preservative-free OTC eye drop for ocular itching associated with allergic conjunctivitis in the second half of 2020. The firm reports its Lumify redness relief drops generated sales of $63m for 2019.
Ensure, Glucerna brands boost Abbott Nutrition adult product third-quarter sales 3.9% on reported basis to $830m; Baush + Lomb relaunches PreserVision AREDS 2 Formula soft gels with easier-to-swallow option; Hum Nutrition Mighty Night supplement boosts skin cell renewal during sleep; and NOW Health Group acquires family-owned SuperNutrition.